Infant Bacterial Therapeutics
39,7 SEK -4,57%Vær den første som følger denne virksomhed
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IBT B
Daglig lav / høj pris
39,7 / 41,8
SEK
Markedsværdi
534,82 mio. SEK
Aktieomsætning
423,58 t SEK
Volumen
10 t
Finanskalender
Delårsrapport
14.11.2024
Årsrapport
13.02.2025
Delårsrapport
07.05.2025
Generalforsamling
08.05.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
SIX SIS AG, W8IMY | 11,1 % | 8,5 % |
Fjärde AP-fonden | 10,0 % | 7,7 % |
Northern Trust Company | 9,9 % | 7,6 % |
Annwall & Rothschild Investment AB | 8,7 % | 29,9 % |
AMF Aktiefond småbolag | 4,5 % | 3,4 % |
Unionen-Svenska | 4,0 % | 3,0 % |
Ålandsbanken ABP | 3,1 % | 2,4 % |
Tredje AP Fonden | 2,8 % | 2,1 % |
Dangoor David | 2,7 % | 2,1 % |
P.R. Banque Pictet & Cie SA | 2,3 % | 1,8 % |
ViserAlle indholdstyper
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2025
IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools